Targeting mTOR signaling for lung cancer therapy

Journal of Thoracic Oncology

Volumn 1, Issue 2, 2006, Pages 109-111

  Sun, Shi Yong ^a   Fu, Haian ^a   Khuri, Fadlo R ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DOCETAXEL; EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN SERINE THREONINE KINASE; RAPAMYCIN; TEMSIROLIMUS; ANTINEOPLASTIC ANTIBIOTIC; DNA; PROTEIN KINASE;

ADENOCARCINOMA; CANCER INHIBITION; CANCER RADIOTHERAPY; CANCER THERAPY; CELL GROWTH; CELL PROLIFERATION; CELL STRESS; CELL SURVIVAL; GENE FREQUENCY; GENE MUTATION; HUMAN; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; MOLECULAR WEIGHT; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; RNA TRANSLATION; SHORT SURVEY; SIGNAL TRANSDUCTION; TRANSLATION INITIATION; DRUG EFFECT; GENETICS; LUNG TUMOR; METABOLISM; MUTATION; PATHOLOGY; REVIEW; TREATMENT OUTCOME;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANTIBIOTICS, ANTINEOPLASTIC; CARCINOMA, NON-SMALL-CELL LUNG; CELL SURVIVAL; DNA, NEOPLASM; HUMANS; LUNG NEOPLASMS; MUTATION; PROTEIN KINASES; SIROLIMUS; TREATMENT OUTCOME;

EID: 34247869651     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/01243894-200602000-00002     Document Type: Short Survey

References (27)

1. Bjornsti MA, Houghton PJ. The TOR pathway: A target for cancer therapy. Natl Rev Cancer 2004;4:335-348.
2. Sawyers CL. Will mTOR inhibitors make it as cancer drugs? Cancer Cell 2003;4:343-348.
3. Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes Dev 2004;18:1926-1945.
4. Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Natl Rev Cancer 2002;2:489-501.
5. Shaw RJ, Bardeesy N, Manning BD, et al. The LKB1 tumor suppressor negatively regulates mTOR signaling. Cancer Cell 2004;6:91-99.
6. Inoki K, Li Y, Zhu T, Wu J, Guan KL. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat Cell Biol 2002;4:648-657.
7. Corradetti MN, Inoki K, Bardeesy N, DePinho RA, Guan KL. Regulation of the TSC pathway by LKB1: Evidence of a molecular link between tuberous sclerosis complex and Peutz-Jeghers syndrome. Genes Dev 2004;18:1533-1538.
8. Downward J. Targeting RAS signaling pathways in cancer therapy. Natl Rev Cancer 2003;3:11-22.
9. Mitsuuchi Y, Testa JR. Cytogenetics and molecular genetics of lung cancer. Am J Med Genet 2002;115:183-188.
10. Sekido Y, Fong KM, Minna JD. Molecular genetics of lung cancer. Annu Rev Med 2003;54:73-87.
11. Hirsch FR, Scagliotti GV, Langer CJ, Varella-Garcia M, Franklin WA. Epidermal growth factor family of receptors in preneoplasia and lung cancer: perspectives for targeted therapies. Lung Cancer 2003;41:S29-S42.
12. Brognard J, Clark AS, Ni Y, Dennis PA. Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Res 2001;61:3986-3997.
13. Lee SH, Kim HS, Park WS, et al. Non-small cell lung cancers frequently express phosphorylated Akt; an immunohistochemical study. APMIS 2002;110:587-592.
14. Balsara BR, Pei J, Mitsuuchi Y, et al. Frequent activation of AKT in non-small cell lung carcinomas and preneoplastic bronchial lesions. Carcinogenesis 2004;25:2053-2059.
15. Tsao AS, McDonnell T, Lam S, et al. Increased phospho-AKT [Ser(473)] expression in bronchial dysplasia: Implications for lung cancer prevention studies. Cancer Epidemiol Biomarkers Prev 2003;12:660-664.
16. David O, Jett J, LeBeau H, et al. Phospho-Akt overexpression in non-small cell lung cancer confers significant stage-independent survival disadvantage. Clin Cancer Res 2004;10:6865-6871.
17. Avizienyte E, Loukola A, Roth S, et al. LKB1 somatic mutations in sporadic tumors. Am J Pathol. 1999;154:677-681.
18. Avizienyte E, Roth S, Loukola A, et al. Somatic mutations in LKB1 are rare in sporadic colorectal and testicular tumors. Cancer Res 1998;58:2087-2090.
19. Sanchez-Cespedes M, Parrella P, Esteller M, et al. Inactivation of LKB1/STK11 is a common event in adenocarcinomas of the lung. Cancer Res 2002;62:3659-3662.
20. Carretero J, Medina PP, Pio R, Montuenga LM, Sanchez-Cespedes M. Novel and natural knockout lung cancer cell lines for the LKB1/STK11 tumor suppressor gene. Oncogene 2004;23:4037-4040.
21. Sun SY, Rosenberg LM, Wang X, et al. Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res 2006;65:7052-7058.
22. Boffa DJ, Luan F, Thomas D, et al. Rapamycin inhibits the growth and metastatic progression of non-small cell lung cancer. Clin Cancer Res 2004;10:293-300.
23. Wislez M, Spencer ML, Izzo JG, et al. Inhibition of mammalian target of rapamycin reverses alveolar epithelial neoplasia induced by oncogenic K-ras. Cancer Res 2006;65:3226-3235.
24. Beuvink I, Boulay A, Fumagalli S, et al. The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation. Cell 2006;120:747-759.
25. Mondesire WH, Jian W, Zhang H, et al. Targeting mammalian target of rapamycin synergistically enhances chemotherapy-induced cytotoxicity in breast cancer cells. Clin Cancer Res 2004;10:7031-7042.
26. Shinohara ET, Cao C, Niermann K, et al. Enhanced radiation damage of tumor vasculature by mTOR inhibitors. Oncogene 2006;24:5414-5422.
27. Wu C, Wangpaichitr M, Feun L, Kuo MT, Robles C, Lampidis T, Savaraj N. Overcoming cisplatin resistance by mTOR inhibitor in lung cancer. Mol Cancer. 2005;4:25.